Corvalol tablets 30 pieces

Pharmacodynamics. Corvalol is a sedative and antispasmodic drug, the effect of which is determined by its components.

Ethyl ester of α-bromizovaleric acid has a reflex sedative and antispasmodic effect, caused by irritation mainly of the receptors of the oral cavity and nasopharynx, a decrease in reflex excitability in the central nervous system and an increase in inhibition phenomena in the neurons of the cortex and subcortical structures of the brain, as well as a decrease in the activity of central vascular centers and a direct local antispasmodic effect on vascular smooth muscle.

Phenobarbital inhibits the activating effect of the centers of the reticular formation of the medulla oblongata on the cerebral cortex, thereby reducing the flow of excitatory influences on the cerebral cortex and subcortical structures. Reducing the activating effects has, depending on the dose, a calming, tranquilizing or hypnotic effect. Corvalol reduces the excitatory effect on the vasomotor centers, coronary and peripheral vessels, reducing overall blood pressure, eliminating and preventing vascular spasms, especially cardiac.

Peppermint oil contains a large number of essential oils, including about 50% menthol and 4-9% menthol esters. They are able to irritate the “cold” receptors of the oral cavity and reflexively dilate mainly the vessels of the heart and brain, stopping spasms of smooth muscles, causing a sedative and mild choleretic effect. Peppermint oil has an antiseptic and antispasmodic effect, has the ability to eliminate the phenomena of flatulence.

Pharmacokinetics. When administered sublingually, absorption begins already in the sublingual region, the bioavailability of active substances is high (about 60-80%). The effect manifests itself quickly (after 5-10 min). When taken orally, the effect develops after 15-45 min and lasts for 3-6 hours. In people who have previously used barbituric acid preparations, the duration of action is reduced due to the accelerated metabolism of phenobarbital in the liver, where barbiturates cause enzyme induction. In the elderly and in patients with cirrhosis of the liver, the metabolism of Corvalol is reduced, so T _½ in them is prolonged, which requires a dose reduction and lengthening of the intervals between doses of the drug.

• Neurosis with increased irritability; insomnia; in complex therapy for hypertension and vegetative-vascular dystonia; pronounced coronary spasms, tachycardia; intestinal spasms associated with neurovegetative disorders (as an antispasmodic drug).

Corvalol is prescribed sublingually (under the tongue) or orally for adults, 1 tablet 2-3 times a day.

If necessary (pronounced tachycardia and spasm of coronary vessels), a single dose can be increased to 3 tablets.

The duration of use of the drug is determined by the doctor depending on the clinical effect and tolerability of the drug.

Children: There is no experience of use in children.

• Hypersensitivity to the components of the drug, bromine; severe liver and/or kidney dysfunction; hepatic porphyria; severe heart failure; severe arterial hypotension; acute myocardial infarction; diabetes mellitus; depression; myasthenia gravis; alcoholism; drug and medical addiction; respiratory diseases with shortness of breath, obstructive syndrome.

Corvalol is usually well tolerated. In some cases, the following side effects are possible:

from the digestive tract: constipation, feeling of heaviness in the epigastric region, with prolonged use – impaired liver function, nausea, discomfort in the stomach and intestines;

from the nervous system: weakness, ataxia, impaired coordination of movements, nystagmus, hallucinations, paradoxical excitement, decreased concentration, fatigue, slowed reactions, headache, cognitive impairment, confusion, drowsiness, mild dizziness;

from the side of the hematopoietic organs: anemia, thrombocytopenia, agranulocytosis;

Immune system disorders: hypersensitivity reactions, including angioedema;

Cardiovascular system: hypotension, bradycardia, slowing of the heart rate;

Skin and mucous membranes: allergic reactions, including skin rashes, itching, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis;

other: difficulty breathing.

Prolonged use of bromine-containing drugs can lead to bromine poisoning, which is characterized by the following symptoms: CNS depression, depressed mood, depression, confusion, ataxia, apathy, conjunctivitis, rhinitis, lacrimation, acne, or purpura.

The risk of developing Stevens-Johnson and Lyell syndrome is greatest in the first weeks of treatment. Long-term use is not recommended due to the risk of developing drug dependence, possible accumulation of bromine in the body and the development of bromine poisoning. In cases where pain in the heart area does not go away after taking the drug, you should consult a doctor to rule out acute coronary syndrome. It is prescribed with caution in hyperkinesia, hyperthyroidism, adrenal hypofunction, decompensated heart failure, acute and persistent pain, acute drug intoxication.

Simultaneous consumption of alcoholic beverages should be avoided.

The drug should be prescribed with caution in cases of arterial hypotension.

The drug contains lactose monohydrate, therefore, if you have an intolerance to some sugars, consult your doctor before using this medicine.

Use during pregnancy or breastfeeding. Do not use during pregnancy or breastfeeding.

The ability to influence the reaction rate when driving or working with other mechanisms. The drug should not be taken by people working with mechanisms, drivers of vehicles, etc.

Drugs with a central depressant type of action enhance the effect of Corvalol.

The presence of phenobarbital in the composition of the drug may induce liver enzymes and, accordingly, may accelerate the metabolism of some drugs that are metabolized by these enzymes (including indirect anticoagulants, cardiac glycosides, antimicrobial, antiviral, antifungal, antiepileptic, anticonvulsant, psychotropic, oral hypoglycemic, hormonal, immunosuppressive, cytostatic, antiarrhythmic, antihypertensive drugs, griseofulvin, glucocorticoids, contraceptives), since their effectiveness will decrease as a result of a higher level of metabolism.

Corvalol enhances the effect of analgesics, local anesthetics, and drugs that depress the CNS.

MAO inhibitors prolong the effect of phenobarbital. Rifampicin may reduce the effect of phenobarbital.

The risk of kidney damage increases when phenobarbital is used simultaneously with gold preparations.

With prolonged simultaneous use of phenobarbital with NSAIDs, there is a risk of stomach ulcer formation and bleeding.

Concomitant use of phenobarbital with zidovudine increases the toxicity of both drugs.

When used simultaneously with valproic acid, its effect is enhanced.

When used simultaneously with methotrexate, the toxicity of the latter increases.

Alcohol enhances the effect of the drug, and also increases its toxicity. While taking the drug, you should avoid drinking alcoholic beverages.

Possible with frequent or prolonged use of the drug, which is associated with the cumulation of its components. Long-term and constant use can cause addiction, withdrawal syndrome, psychomotor agitation. Abrupt cessation of the drug can cause withdrawal syndrome.

Symptoms of overdose: respiratory depression, up to its cessation; CNS depression, confusion, dizziness, ataxia, drowsiness, up to coma; cardiovascular depression, including rhythm disturbances, tachycardia, decreased blood pressure, up to a collaptoid state; nausea, weakness, decreased body temperature, decreased diuresis.

Treatment: symptomatic.

In a place protected from light at a temperature not exceeding 25 ° C. Store out of the reach of children.